DaVita Inc. logo

DaVita Inc. (DVA)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
117. 39
+0.11
+0.09%
$
8.48B Market Cap
16.41 P/E Ratio
0% Div Yield
401,759 Volume
7.83 Eps
$ 117.28
Previous Close
Day Range
117.16 118.72
Year Range
113.97 179.6
Want to track DVA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 68 days
DaVita HealthCare (DVA) Advances But Underperforms Market: Key Facts

DaVita HealthCare (DVA) Advances But Underperforms Market: Key Facts

In the most recent trading session, DaVita HealthCare (DVA) closed at $164.82, indicating a +0.15% shift from the previous trading day.

Zacks | 1 year ago
Can DaVita Stock Continue Its Bull Run After Doubling in a Year?

Can DaVita Stock Continue Its Bull Run After Doubling in a Year?

DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.

Zacks | 1 year ago
DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?

DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 1 year ago
Are Investors Undervaluing DaVita (DVA) Right Now?

Are Investors Undervaluing DaVita (DVA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.

Zacks | 1 year ago
Here's Why You Should Add DaVita Stock to Your Portfolio Now

Here's Why You Should Add DaVita Stock to Your Portfolio Now

DVA's strength in its kidney care business raises optimism about the stock.

Zacks | 1 year ago
Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term

Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Zacks | 1 year ago
5 Stocks Trading Near 52-Week High With Room to Rise Further

5 Stocks Trading Near 52-Week High With Room to Rise Further

Investors target stocks that have been on a bullish run lately. Stocks like THC, SLVM, DVA, NCLH and IAG are seeing price strength, and the momentum is likely to continue.

Zacks | 1 year ago
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors

DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors

DaVita HealthCare (DVA) closed the most recent trading day at $163.08, moving +0.51% from the previous trading session.

Zacks | 1 year ago
Should Value Investors Buy DaVita (DVA) Stock?

Should Value Investors Buy DaVita (DVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?

Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?

Here is how DaVita HealthCare (DVA) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

Zacks | 1 year ago
Loading...
Load More